Open AccessA prospective, randomized, open-label, placebo-controlled comparative study of Bacillus coagulans GBI-30,6086 with digestive enzymes in improving indigestion in geriatric population
Author(s) -
Vaijayanti A. Kumar,
Kulur Mukhyaprana Sudha,
Shilpa Bennur,
Karukkupalayam Ramasamy Dhanasekar
Publication year - 2020
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_922_19
Subject(s) - indigestion , medicine , flatulence , probiotic , tolerability , population , bacillus coagulans , placebo , gastroenterology , adverse effect , food science , pathology , biology , genetics , alternative medicine , environmental health , bacteria , fermentation
Digestive symptoms are common affecting more than 60% of the elderly people. Digestive enzyme deficiency and dysbiosis in the gastric fluid microbiota are the major contributors in the pathophysiology of indigestion. Therefore, therapeutic strategy targeting the gastric microbiota and digestive enzymes has the potential to treat indigestion. This study was conducted to evaluate the efficacy and tolerability of probiotic Bacillus coagulans GBI30,6086 along with digestive enzymes in improving indigestion in geriatric population.